- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Entretinib is an oral tyrosine kinase inhibitor targeting the fusion of ROS1 and NTRK genes, mainly used for the treatment of ROS1 positive non...
Rezdifra is a novel drug, but its specific information is not included in the current search results. According to the existing information, th...
Rezdifra is a novel targeted therapy drug, but specific information about the drug is currently not provided in search results. According to th...
Entretinib is an oral tyrosine kinase inhibitor that targets the fusion of ROS1 and NTRK genes. It is mainly used to treat ROS1 positive non-sm...
Tivozanib is an oral inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase, mainly used for the treatment of advance...
Tivozanib is an oral inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase, mainly used for the treatment of advance...
Selumetinib is a MEK1/2 inhibitor targeted drug mainly used to treat type 1 neurofibromatosis (NF1) - related plexiform neurofibromatosis. It i...
Selumetinib is a MEK1/2 inhibitor targeted drug primarily used to treat type 1 neurofibromatosis (NF1) - related plexiform neurofibromatosis. I...
Dicomit is an antiepileptic drug mainly used to treat seizures in patients with Dravet syndrome (severe myoclonic epilepsy), usually used as an...
Dicomit is an antiepileptic drug used to treat Dravet syndrome, mainly exerting therapeutic effects by regulating GABAergic neurotransmission. ...
